SAMIT GHOSAL

Prof. SAMIT GHOSAL

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
SGSAMIT GHOSAL
SAMIT GHOSAL
BSBinayak Sinha
Binayak Sinha
MMMilan Majumder
Milan Majumder
AMAnoop Misra
Anoop Misra


11 November 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SGSAMIT GHOSAL
SAMIT GHOSAL
DDDebasis Datta
Debasis Datta
BSBinayak Sinha
Binayak Sinha
Treatment options for nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D), two conditions which coexist, are limited though weight loss is an important strategy to improve outcomes in either disease. Glucagon-like peptide 1 receptor agonist (GLP1-RA) present a novel option to treat this dual disease by their salutary effects on glycaemic control and weight reduction. Eight randomized controlled trials on T2D and NAFLD from the Cochrane Library, Embase, and PubMed were included in this meta-analysis. The Comprehensive Meta-Analysis Software version 3 was used to calculate the effect size. In a pooled population of 615 patients—297 on GLP1-RA and 318 in the control arm, GLP1-RA produced a significant improvement in alanine aminotransferase [standardised mean difference (SDM), − 0.56, 95% CI − 0.88 to − 0.25, P < 0.01], aspartate aminotransferase (SDM, − 0.44, SE, 95% CI − 0.64 to − 0.24, P < 0.01), gamma glutaryl transaminase (SDM, − 0.60, 95% CI − 0.86 to − 0.34, P < 0.01) and reduction in liver fat content (LFC) (SDM, − 0.43, 95% CI − 0.74 to − 0.12, P < 0.01), as well as glycosylated haemoglobin (SDM, − 0.40, 95% CI, − 0.61 to − 0.19, P < 0.01) and weight (SDM, − 0.66, 95% CI, − 0.88 to − 0.44, P < 0.01), in comparison to standard of care or placebo. Significant improvement in biopsy resolution was also seen in the GLP1-RA arm (Rate Ratio, 6.60, 95% CI 2.67 to 16.29, P < 0.01). This is possibly the first meta-analysis conducted exclusively in patients with T2D and NAFLD which presents a strong signal that GLP1-RA, improve liver function and histology by improving glycaemia, reducing body weight and hepatic fat, which in turn reduces hepatic inflammation.Trial Registration: PROSPERO (ID: CRD42021228824).

1 July 2020 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
SGSAMIT GHOSAL
SAMIT GHOSAL
SSSumit Sengupta
Sumit Sengupta
MMMilan Majumder
Milan Majumder
BSBinayak Sinha
Binayak Sinha

1 July 2020 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
SGSAMIT GHOSAL
SAMIT GHOSAL
RBRahul Bhattacharyya
Rahul Bhattacharyya
MMMilan Majumder
Milan Majumder

1 September 2020 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
SGSAMIT GHOSAL
SAMIT GHOSAL
BABhavya Arora
Bhavya Arora
KDKoel Dutta
Koel Dutta
AGAmerta Ghosh
Amerta Ghosh
BSBinayak Sinha
Binayak Sinha
AMAnoop Misra
Anoop Misra